University of Oxford - United Kingdom
AUTHOR PROFILE
Scopus
Orcid
EARLY ACADEMIC PURSUITS:
Siim Pauklin embarked on his academic journey with a Bachelor's degree in Molecular and Cell Biology from the University of Tartu in Estonia, earning the distinction of Diploma Cum Laude in 2004. He further pursued his academic interests with a Master's degree in Molecular and Cell Biology at the same institution, completing it with distinction in 2005. His early academic pursuits showcased exceptional dedication and achievement in the field.
PROFESSIONAL ENDEAVORS:
Following his Master's degree, Siim Pauklin expanded his academic horizons with a Ph.D. in Biochemistry and Molecular Biology at University College London / CRUK London Research Institute from September 2005 to October 2009. His Ph.D. research, titled "Regulation of Activation Induced Deaminase (AID)," not only earned him the prestigious Pontecorvo prize for the best thesis in CRUK but also led to groundbreaking discoveries in the regulation of AID expression by hormones and its role in immune responses, autoimmune diseases, and tumorigenesis.
Siim Pauklin's research has been instrumental in advancing our understanding of stem cell biology and cancer research, particularly in the molecular mechanisms regulating cancer stem cell formation. His work on the TGFß/Activin/Nodal-SMAD2/3 signaling pathway in pancreatic ductal adenocarcinomas and cancer stem cells has paved the way for insights into chemoresistance, metastatic capacity, and the 3D chromatin architecture of pancreatic cancer.
IMPACT AND INFLUENCE:
Siim Pauklin's impact in the field is evident from his career trajectory, securing prestigious fellowships, awards, and recognition for his significant contributions. His leadership as a Principal Investigator and CRUK Career Development Fellow at the University of Oxford underscores his influence in the scientific community.
LEGACY AND FUTURE CONTRIBUTIONS:
Siim Pauklin's research focus on Targeted cancer therapy and pancreatic cancer. As he continues to lead his research group at the University of Oxford, his commitment to uncovering early detection methods and advancing therapeutic strategies for cancer stem cells promises a lasting impact on the field. His future contributions are anticipated to further shape our understanding of cancer biology and contribute to the development of novel cancer therapies.
NOTABLE PUBLICATIONS
BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma. 2023
KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. 2023
Epigenetic and transcriptional regulations prime cell fate before division during human pluripotent stem cell differentiation.2023